ARCUTIS BIOTHERAPEUTICS, INC. (ARQT)

Every figure this model derived for ARQT, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 158,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 238,552,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 467,671,000 AssetsCurrent 2026-06-30
current liabilities 160,340,000 LiabilitiesCurrent 2026-06-30
equity 220,579,000 StockholdersEquity 2026-06-30
interest expense 13,846,000 InterestExpenseNonoperating 2026-06-30
ocf -5,625,000 NetCashProvidedByUsedInOperatingActivities 2025-12-31
revenue 463,981,000 Revenues 2026-06-30
sbc 43,549,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ARQT on one particular measure came for.

RatioValue
cash operating margin16.92
current ratio2.92
current ratio reported2.92
dilution pct5.19
fcf margin-1.25
growth cv1.05
interest cover2.47
operating margin7.38
owner earnings margin-10.63
revenue growth76.11
revenue growth per share67.41
roic27.65
rule of 4083.49
sbc pct revenue9.39

What to be careful about

What this model itself distrusts about ARQT's figures. Written by the derivation as it ran, not added afterwards.